View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Szentkirályi u. 46., 1088
  • 2 MTA–SE Molekuláris Medicina Kutatócsoport, Budapest

Absztrakt:

A nem alkoholos zsírmájbetegség (NAFLD) a fejlett országokban a populáció harmadát érintő metabolicus népbetegség. A magas prevalencia mellett a NAFLD jelentőségét a spektrumbetegség (steatosis → NASH [nem alkoholos steatohepatitis] ± fibrosis → cirrhosis → HCC [hepatocellularis carcinoma]) jellege, illetve a társuló kórállapotok (obesitas, 2-es típusú diabetes mellitus, dyslipidaemia, metabolicus szindróma, inzulinrezisztencia), valamint mind a májbetegség közvetlen progressziójából adódó hepaticus, mind a társuló anyagcserezavar progressziójához kapcsolódó célszervkárosodás (cardiovascularis, renalis) adja. A NAFLD diagnosztikus, terápiás, illetve követési algoritmusának egységesebb kialakítására három európai szakmai társaság (EASL–EASD–EASO) összefogásával 2016-ban jelent meg a hiánypótlónak számító klinikai szakmai irányelv. Az eredeti közleményben kiemelt ajánlási pontok szó szerinti fordításra kerülhettek, ugyanakkor az ehhez társuló magyarázó részek – a terjedelmi korlátok miatt – a jelen közleményben nem voltak egy az egyben ismertethetők, így a közlemény szerzői ezekből csak a leglényegesebb szempontok kiemelésére, sőt egy-egy esetben az ajánlás óta megjelent új irodalmak ismertetésére törekedhettek. Orv Hetil. 2018; 159(45): 1815–1830.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014; 20: 9072–9089.

  • 2

    World Gastroenterology Organisation Global Guidelines. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Available from: http://www.worldgastroenterology.org/guidelines/global-guidelines/nafld-nash [accessed: October 04, 2017].

  • 3

    European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64: 1388–1402.

  • 4

    Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.

  • 5

    Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012; 27: 1555–1560.

  • 6

    Borch-Johnsen K, Wareham N. The rise and fall of the metabolic syndrome. Diabetologia 2010; 53: 597–599.

  • 7

    Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27: 978–983.

  • 8

    Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLOS ONE 2010; 5: e12226.

  • 9

    Bril F, Cusi K. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2016; 45: 765–781.

  • 10

    Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017; 23: 1–12.

  • 11

    Hassan MM, Kaseb A, Etzel CJ, et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013; 52(S1): 139–147.

  • 12

    Donati B, Motta BM, Pingitore P, et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology 2016; 63: 787–798.

  • 13

    Rosta K, Al-Aissa Z, Hadarits O, et al. Association study with 77 SNPs confirms the robust role for the rs10830963/G of MTNR1B variant and identifies two novel associations in gestational diabetes mellitus development. PLOS ONE 2017; 12: e0169781.

  • 14

    Reference SNP (refSNP) Cluster Report: rs738409 – Population genetics – Homo sapiens – GRCh37 Archive browser 90. http://grch37.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=22:44324227-44325227;v=rs738409;vdb=variation;vf=528620

  • 15

    Hagymási K, Lengyel G. Non-alcoholic steatosis/steatohepatitis – 2010. [Nem alkoholos steatosis/steatohepatitis – 2010.] Orv. Hetil. 2010; 151: 1940–1945. [Hungarian]

  • 16

    Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082–1090.

  • 17

    Karlas T, Petroff D, Garnov N, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLOS ONE 2014; 9: e91987.

  • 18

    Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012; 36: 22–29.

  • 19

    Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999; 276: E977–E989.

  • 20

    Krššák M, Hofer H, Wrba F, et al. Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy. Eur J Radiol. 2010; 74: e60–e66.

  • 21

    Dendl LM, Schreyer AG. Steatosis hepatis – a challenge? [Steatosis hepatis – eine Herausforderung?] Radiologe 2012; 52: 745–752. [German]

  • 22

    Rustogi R, Horowitz J, Harmath C, et al. Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. J Magn Reson Imaging 2012; 35: 1356–1364.

  • 23

    Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–357.

  • 24

    Bedossa P, the FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60: 565–575.

  • 25

    Manco M, Alisi A, Nobili V. Risk of severe liver disease in NAFLD with normal ALT levels: a pediatric report. Hepatology 2008; 48: 2087–2088.

  • 26

    Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes developing. Lancet 2012; 379: 2279–2290.

  • 27

    Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. [Szérum dipeptidil peptidase-4 aktivitás inzulinrezisztens nem alkoholos zsírmáj-betegekben : a májbetegség új biomarkere.] Metabolizmus 2013; 11: 339–347. [Hungarian]

  • 28

    Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917–1925.

  • 29

    Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care 2013; 36: 2294–2300.

  • 30

    Kang YM, Jung CH, Cho YK, et al. Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population. PLOS ONE 2017; 12: e0175762.

  • 31

    Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792–798.

  • 32

    American Diabetes Association. 3. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes – 2018. Diabetes Care 2018; 41(Suppl 1): S28–S37.

  • 33

    Jermendy Gy. (ed.) Health care professional guideline – the diagnosis, antihyperglicemic treatment and care of diabetes mellitus in adults. [Egészségügyi szakmai irányelv – A diabetes mellitus kórismézéséről, a cukorbetegek antihyperglykaemiás kezeléséről és gondozásáról felnőttkorban.] Diabetol Hung. 2017; 25: 3–77. [Hungarian]

  • 34

    Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012; 35: 873–878.

  • 35

    Pár A, Pár G. Advances in the pathogenesis of non alcoholic fatty liver disease. [Újabb adatok a nem alkoholos zsírmáj patogeneziséhez.] Orv Hetil. 2017; 158: 882–894. [Hungarian]

  • 36

    Blond E, Disse E, Cuerq C, et al. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia 2017; 60: 1218–1222.

  • 37

    Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care? Atherosclerosis 2013; 230: 258–267.

  • 38

    Minhas AM, Usman MS, Khan MS, et al. Link between non-alcoholic fatty liver disease and atrial fibrillation: a systematic review and meta-analysis. Cureus 2017; 9: e1142.

  • 39

    Pár A, Pár G. Non-alcoholic fatty liver disease and hepatocellular carcinoma – 2016. [Nem alkoholos zsírmáj és hepatocellularis carcinoma – 2016.] Orv Hetil. 2016; 157: 987–994. [Hungarian]

  • 40

    Pár A, Pár G. Non alcoholic fatty liver. [Nem alkoholos zsírmáj.] Orvostovábbk Szle. 2017; 24: 48–56. [Hungarian]

  • 41

    Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121–129.

  • 42

    Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016; 20: 339–350.

  • 43

    Smajis S, Gajdosik M, Krssak M, et al. Unravelling the pathogenetic mechanisms of fructose consumption as multiple hit in the pathogenesis and progression of non-alcoholic fatty liver disease. Diabetologia 2017; 60(Suppl 1): S6.

  • 44

    Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679–690.

  • 45

    Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011; 306: 1549–1556.

  • 46

    Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 2010; 341: c5702.

  • 47

    Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842–857.

  • 48

    Athyros VG, Boutari C, Stavropoulos K, et al. Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk. Curr Vasc Pharmacol. 2018; 16: 246–253.

  • 49

    Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5: 1544–1560.

  • 50

    Halmos T, Suba I. Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases. [A nem alkoholos zsírmáj mint a metabolikus szindróma komponense és kauzális kapcsolatai egyéb kórképekkel.] Orv. Hetil. 2017; 158: 2051–2061. [Hungarian]

  • 51

    Armstrong MJ, Hazlehurst JM, Hull D, et al. Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab. 2014; 16: 651–660.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Sep 2020 0 48 52
Oct 2020 0 40 43
Nov 2020 0 28 24
Dec 2020 0 19 20
Jan 2021 0 27 28
Feb 2021 0 21 22
Mar 2021 0 1 1